Proudly running biotech firm iBio (NYSE: IBIO) in New York for long years today breaks historically $400 million barrier of the market capitalization which is overstated as compared to the actual value, of course.
By surging over 30% IBIO is very close to $400 million and a 50% rise could actually show more than that value. Now the daily volume is crucial to break that wall and before the market closes the management of iBio may celebrate the historical market value.
iBio is one of the COVID-19 vaccine developers, so far its program is far behind Moderna, CureVac, T2 vaccine development processes. Hopefully, iBio is doing it with full energy and enthusiasm to cure the whole world by available resources.
Editor in Chief.
Living in the era of dynamic tech change Alex decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring in Finance) writing for technology and as well as finance has been one of the precious aspects of his life